

118TH CONGRESS
2D SESSION

H. R. 9598

To amend the Office of National Drug Control Policy Reauthorization Act to reauthorize such Office, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 16, 2024

Mr. COMER (for himself, Mr. RASKIN, Mr. DUARTE, Mr. NADLER, Mrs. GONZÁLEZ-COLÓN, and Ms. PLASKETT) introduced the following bill; which was referred to the Committee on Oversight and Accountability, and in addition to the Committees on the Judiciary, and Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To amend the Office of National Drug Control Policy Reauthorization Act to reauthorize such Office, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-
2 tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Office of National
5 Drug Control Policy Reauthorization Act of 2024”.

1 SEC. 2. OFFICE OF NATIONAL DRUG CONTROL POLICY RE-

2 **AUTHORIZATION.**

3 (a) AMENDMENTS TO THE OFFICE OF NATIONAL
4 DRUG CONTROL POLICY REAUTHORIZATION ACT OF
5 1998.—The Office of National Drug Control Policy Reau-
6 thorization Act of 1998 (21 U.S.C. 1701 et seq.) is
7 amended—

8 (1) in section 702 (21 U.S.C. 1701)—
9 (A) in paragraph (2)(A)(ii), by striking
10 “Government Reform” and inserting “Account-
11 ability”;

12 (B) in paragraph (3)—
13 (i) in subparagraph (L), by striking “;”
14 and” and inserting a semicolon;
15 (ii) in subparagraph (M), by striking
16 the period at the end and inserting “;”
17 and”; and

18 (iii) by adding at the end the fol-
19 lowing:

20 “(N) tertiary prevention support or serv-
21 ices, including opioid antagonists or overdose
22 reversal agents such as naloxone, and other
23 harm reduction activities such as overdose and
24 drug detection testing.”;

25 (C) by amending paragraph (7) to read as
26 follows:;

1 “(7) EMERGING DRUG THREAT.—The term
2 ‘emerging drug threat’ means the occurrence of a
3 new and growing trend in the illicit use or misuse
4 of a drug, class of drugs, or non-controlled sub-
5 stance, or a new or evolving method of drug con-
6 sumption or trafficking, including rapid expansion in
7 the supply of or demand for such a drug or sub-
8 stance.”;

9 (D) in paragraph (9), by striking “drug
10 laws” and inserting the following: “drug, trade,
11 and illicit drug trafficking laws”;

12 (E) in paragraph (10), by inserting after
13 “demand reduction,” the following: “illicit drug
14 trafficking.”;

15 (F) by redesignating paragraphs (15),
16 (16), and (17) as paragraphs (17), (18), and
17 (19), respectively;

18 (G) by inserting after paragraph (14) the
19 following new paragraph:

20 “(15) PRECURSOR CHEMICAL.—

21 “(A) IN GENERAL.—The term ‘precursor
22 chemical’ includes a listed chemical and an un-
23 regulated precursor.

24 “(B) LISTED CHEMICAL.—The term ‘listed
25 chemical’ has the meaning given that term in

1 section 102 of the Controlled Substances Act
2 (21 U.S.C. 802).

3 “(C) UNREGULATED PRECURSOR.—The
4 term ‘unregulated precursor’—

5 “(i) means any chemical used in the
6 production of illicit drugs that has not
7 been identified as a listed chemical under
8 the Controlled Substances Act; and

9 “(ii) does not include a solvent or rea-
10 gent.

11 “(16) STATE.—The term ‘State’ means each of
12 the several States of the United States, the District
13 of Columbia, and each territory or possession of the
14 United States.”;

15 (H) in paragraph (19), as so redesign-
16 nated—

17 (i) by redesignating subparagraphs
18 (G) and (H) as subparagraphs (H) and
19 (I), respectively; and

20 (ii) by inserting after subparagraph
21 (F) the following:

22 “(G) activities to map, track, dismantle,
23 and disrupt the financial enablers of drug traf-
24 ficking organizations, transnational criminal or-
25 ganizations, and money launderers involved in

1 the manufacture and trafficking of drugs in the
2 United States and in foreign countries;”; and

3 (I) by inserting at the end the following:

4 “(20) UNITED STATES.—The term ‘United
5 States’, when used in a geographical sense, means
6 all of the States, the District of Columbia, and the
7 territories and possessions of the United States, and
8 any waters within the jurisdiction of the United
9 States.

10 “(21) EVIDENCE.—The term ‘evidence’ has the
11 meaning given that term in section 3561 of title 44,
12 United States Code.”;

13 (2) in section 703(d) (21 U.S.C. 1702(d))—

14 (A) in paragraph (5)(B), by striking “ac-
15 cepted by a contractor to be used in its per-
16 formance of a contract for the Office” and in-
17 serting the following: “accepted—

18 “(i) by a contractor (or subcontractor
19 thereof at any tier) for use in its perform-
20 ance of a contract for the Office; or

21 “(ii) by a grant recipient (or sub-
22 grantee thereof at any tier) for use in car-
23 rying out an award related to a fund ad-
24 ministered by the Office.”; and

(B) in paragraph (6), by inserting after “paragraph (5)” the following: “and the registry shall be sent to the appropriate Congressional committees”;

(3) in section 704 (21 U.S.C. 1703)—

(A) in subsection (a)(1)(C), by striking “shall” and inserting “may”;

(B) in subsection (b)—

(i) in paragraph (16), by inserting after “to treat addiction” the following: “, encourage primary substance use prevention, and increase accessibility and effectiveness of life-saving opioid antagonists or reversal agents, such as naloxone”;

(ii) by striking paragraph (20);

(iii) by redesignating paragraph (21) as paragraph (20);

(iv) in paragraph (20), as so redesignated, by striking the period at the end and inserting “; and”; and

(v) by inserting at the end the following:

“(21) shall coordinate with the Secretary of Homeland Security, the Attorney General, and the Secretary of State regarding the status of the en-

1 forcement of clauses (i) and (ii) of subparagraph (A)
2 and subparagraph (B) of section 237(a)(2) (8
3 U.S.C. 1227(a)(2)) and subparagraphs (A) and (C)
4 of section 212(a)(2) (8 U.S.C. 1182(a)(2)) for the
5 purposes of ensuring such drug control and illicit
6 drug trafficking enforcement activities are ade-
7 quately resourced.”;

8 (C) in subsection (c)—

9 (i) in paragraph (1)(C), by striking
10 “supply reduction, and State, local, and
11 tribal affairs, including any drug law en-
12 forcement activities” and inserting the fol-
13 lowing: “supply reduction, accessibility to
14 life-saving opioid antagonists or reversal
15 agents, such as naloxone, and State, local,
16 and Tribal affairs, including any drug re-
17 lated law enforcement activities”;

18 (ii) in paragraph (3)(C)—

19 (I) in clause (ii), by inserting
20 after “United States” the following: “,
21 including at and between the ports of
22 entry,”;

23 (II) in clause (iii), by striking “;
24 and” and inserting a semicolon;

(III) in clause (iv), by striking the period at the end and inserting “; and”; and

(IV) by inserting at the end the following new clause:

“(v) requests funding for activities facilitate illicit drug use, but not including overdose reversal medications, drug testing, or testing technology.”;

19 (E) in subsection (i)—

(ii) in paragraph (2), by striking “2023” and inserting “2031”; and

(F) in subsection (k)—

(i) in the heading, by striking “HARM REDUCTION PROGRAMS” and inserting “SUBSTANCE USE PREVENTION, HARM REDUCTION, AND LIFE-SAVING TREATMENT PROGRAMS”; and

(ii) in the first sentence, by inserting after “drug addiction and use” the following: “with the primary goal being the prevention of initial or continued use and the fostering of life-saving opioid antagonists or reversal agents, such as naloxone”;

(4) in section 705 (21 U.S.C. 1704)—

(A) in subsection (a)(3)—

(i) in subparagraph (A), by inserting after “Federal Government” the following: “and such lands owned by a foreign principal (as such term is defined in section 1(b) of the Foreign Agents Registration Act of 1938 (22 U.S.C. 611))”;

(ii) in subparagraph (B)—

(I) by inserting after "the preceding year" the following: ", along

1 with historical comparisons over the
2 prior 20 years.”;

3 (II) in clause (i)—

4 (aa) by inserting after “seiz-
5 ing drugs,” the following: “in-
6 cluding precursor chemicals.”;
7 and

8 (bb) by striking “; and” and
9 inserting a semicolon;

10 (III) in clause (ii), by striking
11 the period at the end and inserting “;
12 and”; and

13 (IV) by inserting at the end the
14 following new clause:

15 “(iii) the effects of trends of encoun-
16 ters of inadmissible aliens at and between
17 the ports of entry, and the effect of any in-
18 creases or changes in the level of trade and
19 travel, on the capacity and ability of the
20 Department of Homeland Security compo-
21 nents to interdict and prevent the unlawful
22 entry of illicit drugs into the United States
23 by any means.”; and

24 (iii) in subparagraph (D)—

1 (I) by inserting after “the pre-
2 ceding year” the following: “, along
3 with historical comparisons over the
4 prior 20 years;” and

(II) in clause (iii), by inserting after "seizing drugs," the following:
"including precursor chemicals,";

12 (C) in subsection (f)—

(ii) by striking paragraph (4);

19 (5) in section 706 (21 U.S.C.

20 (A) in subsection (c)—

1 (aa) by inserting after
2 “identifying existing” the fol-
3 lowing: “evidence,”; and

(bb) by striking “will obtain such data” and inserting “will ensure such data is obtained”;

(III) in subparagraph (J)(ii), by inserting “evidence,” before “data”;

9 (IV) in subparagraph (L), by in-
10 serting “evidence” after “Such other”;
11 and

12 (V) in subparagraph (M)(iv), by
13 inserting “storing and retrieving,”
14 after “collecting.”

15 (ii) in paragraph (2)—

16 (I) by redesignating subparagraphs (E) and (F) as subparagraphs
17 (G) and (H), respectively; and
18

19 (II) by inserting after subparagraph-
20 graph (D) the following new subparagraph-
21 graphs:

24 “(F) The Chief Data Officers Council.”;

25 (iii) in paragraph (3)—

1 “(I) set forth the strategy of the
2 Federal Government for preventing
3 the illegal trafficking of drugs through
4 the Caribbean region into the United
5 States, including through ports of
6 entry, between ports of entry, and
7 across air and maritime approaches;

8 “(II) state the specific roles and
9 responsibilities of each relevant Na-
10 tional Drug Control Program agency
11 for implementing the strategy;

12 “(III) identify the specific re-
13 sources required to enable the relevant
14 National Drug Control Program agen-
15 cies to implement the strategy, to the
16 extent practicable; and

17 “(IV) be designed to promote,
18 and not hinder, legitimate trade and
19 travel.

20 “(ii) SPECIFIC CONTENT RELATED TO
21 PUERTO RICO AND THE UNITED STATES
22 VIRGIN ISLANDS.—The Caribbean Border
23 Counternarcotics Strategy shall include—

24 “(I) a strategy to prevent the il-
25 legal trafficking of drugs to or

1 through Puerto Rico and the United
2 States Virgin Islands, including meas-
3 ures to substantially reduce drug-re-
4 lated violent crime on such islands;
5 and

6 “(II) recommendations for addi-
7 tional assistance or authorities, if any,
8 needed by Federal, State, and local
9 law enforcement agencies relating to
10 the strategy, including an evaluation
11 of Federal technical and financial as-
12 sistance, infrastructure capacity build-
13 ing, and interoperability deficiencies.”;
14 and

15 (iv) in paragraph (5), by striking
16 “data” each place it appears and inserting
17 “evidence, data.”;

18 (B) in subsection (f)—

19 (i) in paragraph (1), by striking “pub-
20 licly available in a machine-readable for-
21 mat” and inserting the following: “publicly
22 available as an open Government data
23 asset (as such term is defined in section
24 3502 of title 44, United States Code)”;

7 “(3) DATA.—The data included in the Drug
8 Control Data Dashboard shall be updated annually
9 with final data, and to the extent practicable, up-
10 dated quarterly with provisional data, that aligns
11 with the goals of the performance measurement sys-
12 tem required under subsection (h) and include, at a
13 minimum, the following:

14 “(A) For each substance identified by the
15 Director as having a significant impact on illicit
16 drug use in the United States, data sufficient
17 to—

“(ii) assess drug use behaviors:

“(iii) estimate the prevalence of substance use disorders;

“(iv) show the number of fatal and non-fatal overdoses; and

1 “(v) assess the provision of substance
2 use disorder treatment.

3 “(B) Any quantifiable measures the Direc-
4 tor determines to be appropriate to detail
5 progress toward the achievement of the goals of
6 the National Drug Control Strategy, including,
7 to the extent practicable, data disaggregated by
8 specific geographic areas or sub-populations of
9 interest.

10 “(C) Data sufficient to assess the effective-
11 ness of such substance use disorder treatments.

12 “(D) To the extent practicable, data suffi-
13 cient to show the extent of prescription drug di-
14 version, trafficking, and misuse in the calendar
15 year and each of the previous 3 calendar years.

16 “(E) Any quantifiable measures the Direc-
17 tor determines to be appropriate to detail
18 progress toward the achievement of the goals of
19 the National Drug Control Strategy, including
20 to the extent practicable, data disaggregated by
21 specific geographic areas or sub-populations of
22 interest.”; and

23 (C) in subsection (g)(2)—

24 (i) in subparagraph (D), by striking
25 “narcotics” and inserting “drugs”;

7 (6) in section 707 (21 U.S.C. 1706)—

(A) in subsection (l)(2)(F), by inserting
“and authorities enforcing illicit drug traf-
ficking laws” after “task forces”;

14 (C) in subsection (p)—

15 (i) in paragraph (5). by striking “;
16 and” and inserting a semicolon:

20 (iii) by inserting at the end the fol-
21 lowing new paragraph:

“(7) \$298,579,000 for each of fiscal years 2025 through 2031.”;

24 (D) in subsection (s)—

(ii) in paragraph (2), by striking “;
and” and inserting a semicolon;

7 (iii) in paragraph (3), by striking the
8 period at the end and inserting “; and”;
9 and

10 (iv) by adding at the end the fol-
11 lowing:

12 “(4) enhancing fentanyl seizure and interdiction
13 activities.”; and

14 (E) by adding at the end the following:

15 "(t) SUPPLEMENTAL GRANTS FOR FENTANYL

16 INTERDICTION ACTIVITIES.—

17 “(1) MINIMUM ALLOCATION OF FUNDS FOR
18 FENTANYL INTERDICTION ACTIVITIES.—Of the
19 amounts allocated for grants under subsection (s),
20 not less than \$5,000,000 shall be allocated for the
21 purpose of making grants under subsection (s)(4).

22 “(2) ADDITIONAL FUNDS.—In addition to
23 amounts allocated under subparagraph (A) for the
24 purpose of making grants under subsection (s)(4),

1 the Director may use amounts otherwise appro-
2 priated to carry out this section for such purpose.

3 “(u) ADDITIONAL JUDICIARY PROSECUTORIAL RE-
4 SOURCES.—

5 “(1) TEMPORARY REASSIGNMENT OF ASSIST-
6 ANT UNITED STATES ATTORNEYS.—

7 “(A) AUTHORITY.—The Attorney General
8 may identify assistant United States attorneys
9 who may be made available for temporary reas-
10 signment under subsection (b)(2) for a period
11 of time determined by the Attorney General in
12 coordination with the Director, during which an
13 assistant United States attorney shall prioritize
14 the investigation and prosecution of organiza-
15 tions and individuals trafficking in fentanyl or
16 fentanyl analogues.

17 “(B) EXTENSION OF REASSIGNMENT.—
18 Such reassignment may be extended by the At-
19 torney General for such time as may be nec-
20 essary to conclude any ongoing investigation or
21 prosecution in which the assistant United
22 States attorney is engaged.

23 “(2) PROCESS FOR TEMPORARY REASSIGN-
24 MENT.—The Attorney General may establish a proc-
25 ess under which the Director, in consultation with

1 the Executive Boards of each designated high inten-
2 sity drug trafficking area, may request such an as-
3 sistant United States attorney to be so temporarily
4 reassigned.

5 “(v) USE OF FUNDS TO COMBAT FENTANYL TRAF-
6 FICKING.—

7 “(1) REQUIREMENT.—As part of the docu-
8 mentation that supports the President’s annual
9 budget request for the Office, the Director shall sub-
10 mit to Congress a report describing the use of
11 HIDTA funds for the purposes of enhancing
12 fentanyl seizure and interdiction activities under
13 subsection (s)(4) or (t) and to investigate and pros-
14 ecute organizations and individuals trafficking in
15 fentanyl or fentanyl analogues in the prior calendar
16 year.

17 “(2) CONTENTS.—The report shall include—

18 “(A) the amounts of fentanyl or fentanyl
19 analogues seized by HIDTA-funded initiative in
20 the area during the previous year; and

21 “(B) law enforcement intelligence and pre-
22 dictive data from the Drug Enforcement Ad-
23 ministration showing patterns and trends in
24 abuse, trafficking, and transportation in
25 fentanyl and fentanyl analogues.

1 “(w) REPORT ON DATA ANALYTICAL SERVICES PRO-
2 GRAM.—

3 “(1) REPORT.—With respect to the Data Ana-
4 lytical Services program (formally known as Hemis-
5 phere), and any successor program, the Director
6 shall submit to the Committee on Oversight and Ac-
7 countability and the Committee on the Judiciary of
8 the House of Representatives, and the Committee on
9 the Judiciary of the Senate a report every two years
10 on any activities of the program—

11 “(A) funded by the Office; and
12 “(B) carried out in two years prior to the
13 submission of the report.

14 “(2) CONTENTS OF REPORT.—The report re-
15 quired by paragraph (1) shall include the following:

16 “(A) A documentation of any activities of
17 the Data Analytical Services program, includ-
18 ing—

19 “(i) the amount of searches conducted
20 for each HIDTA; and

21 “(ii) each requesting local law enforce-
22 ment jurisdiction.

23 “(B) Information on how the program was
24 funded and how funds were expended under the
25 program, including information on any—

1 “(i) funding sources derived from
2 each HIDTA’s funding allocation for a
3 HIDTA, or any other source of funding,
4 for the program; and

5 “(ii) payments made by the program
6 to any non-governmental entity or external
7 vendor.

8 “(C) A description of any policies and
9 guidelines provided to HIDTA personnel and
10 local law enforcement jurisdictions governing
11 the operation of the program in order to ensure
12 that such program does not infringe on rights
13 protected under the Fourth Amendment or vio-
14 late legally protected privacy of United States
15 citizens or individuals legally in the United
16 States, along with any recommendations by the
17 Director to strengthen such policies and guide-
18 lines.”;

19 (7) in section 709(f)(1) (21 U.S.C. 1708(f)(1)),
20 by striking “shall” and inserting “may”;

21 (8) in section 709 (21 U.S.C. 1708)—

22 (A) in subsection (f)(2)(B)(iii), by insert-
23 ing after “professionals” the following: “includ-
24 ing experts in evidence-based media campaigns,
25 education, and evaluation”; and

(B) in subsection (g), by striking “2023” and inserting “2031”;

11 (b) AMENDMENTS TO THE ANTI-DRUG ABUSE ACT
12 OF 1988.—The Anti-Drug Abuse Act of 1988 (Public Law
13 100–690) is amended—

18 (2) in section 1032(b) (21 U.S.C. 1532(b))—

19 (A) by striking “\$125,000” each place the
20 term appears and inserting “\$150,000”; and

21 (B) in paragraph (3)—

22 (i) by striking subparagraph (A) and
23 inserting the following:

24 “(A) IN GENERAL.—Subject to subparagraph
25 graph (F), the Administrator may award up to

1 2 additional grants under this paragraph to an
2 eligible coalition awarded a grant under para-
3 graph (1) or (2) for any first fiscal year after
4 the end of the 4-year or 9-year period following
5 the period of the initial or subsequent grant
6 under paragraph (1) or (2), as the case may
7 be.”;

8 (ii) in subparagraph (B), by striking
9 “a renewal grant” and inserting “up to 2
10 renewal grants”;

11 (iii) in subparagraph (C), by striking
12 “an additional grant” and inserting “the
13 additional grants”; and

14 (iv) by striking subparagraph (D) and
15 inserting the following:

16 “(D) RENEWAL GRANTS.—Subject to sub-
17 paragraph (F), the Administrator may award a
18 renewal grant to a grant recipient under this
19 paragraph for each fiscal year of the 4-fiscal-
20 year period following the first fiscal year for
21 which an additional grant under this paragraph
22 is awarded in an amount not to exceed the
23 amount of non-Federal funds raised by the coa-
24 lition, including in-kind contributions, for that
25 fiscal year.”.

1 (c) REAUTHORIZATION OF THE NATIONAL COMMU-
2 NITY ANTI-DRUG COALITION INSTITUTE.—Section 4(d)
3 of Public Law 107–82 (21 U.S.C. 1521 note) is amended
4 by striking “section 1032 of the National Narcotics Lead-
5 ership Act of 1988 (15 U.S.C. 1532), make a grant of
6 \$2 million under subsection (a), for each of the fiscal years
7 2018 through 2023” and inserting “section 1024 of the
8 National Narcotics Leadership Act of 1988 (21 U.S.C.
9 1524), make a grant of \$2,500,000 under subsection (a),
10 for each of the fiscal years 2025 through 2031”.

11 (d) REAUTHORIZATION OF COMMUNITY-BASED COA-
12 LITION ENHANCEMENT GRANTS TO ADDRESS LOCAL
13 DRUG CRISES.—Subsection (i) of section 103 of the Com-
14 prehensive Addiction and Recovery Act of 2016 (21 U.S.C.
15 1536) is amended by inserting before the period at the
16 end the following: “and \$5,200,000 for each of fiscal years
17 2025 through 2031”.

18 (e) REPORT REGARDING LIFE-SAVING OPIOID AN-
19 TAGONISTS OR REVERSAL AGENTS.—The Office of Na-
20 tional Drug Control Policy Reauthorization Act of 2006
21 (Public Law 109–469) is amended by adding at the end
22 the following new section:

1 **“SEC. 1121. REQUIREMENT FOR LIFE-SAVING OPIOID OVER-**2 **DOSE REVERSAL STUDY.**

3 “(a) FINDING.—Congress finds that it is vital to sup-
4 port access to treatment and emergency intervention tools
5 to address drug addiction while also pursuing strategies
6 to ensure communities have readily available access to life-
7 saving drug overdose reversal medications, including
8 opioid antagonists or reversal agents, such as naloxone,
9 in case of an emergency.

10 “(b) REPORT.—Not later than 180 days after the
11 date of the enactment of this section, the Director of the
12 Office of National Drug Control Policy shall submit to
13 Congress a report that contains the following:

14 “(1) A summary of the relevant roles, respon-
15 sibilities, and authorities of each relevant National
16 Drug Control Program agency to ensure that life-
17 saving drug overdose reversal medications are read-
18 ily available in case of an emergency, including life-
19 saving opioid antagonists or reversal agents, such as
20 naloxone, across the Nation.

21 “(2) A strategy for the Federal Government to
22 ensure that State, local, and Tribal governments,
23 and agencies thereof including law enforcement and
24 public health and safety entities, have life-saving
25 drug overdose reversal medications readily available
26 in case of an emergency, including life-saving opioid

1 antagonists or reversal agents, such as naloxone,
2 which at a minimum identifies—

3 “(A) any Federal and State policies and
4 actions necessary for the relevant National
5 Drug Control Program agencies to take to ad-
6 dress—

7 “(i) the challenges faced by phar-
8 macists, prescription drug providers, dis-
9 pensers (including manufacturers, distribu-
10 tors, and retailers), and other health care
11 providers, to make such medications read-
12 ily available to patients over the counter
13 for emergency use;

14 “(ii) the challenges faced by phar-
15 macists, health care providers, and State
16 health officials to educate the public on the
17 risks and benefits of such medications, in-
18 cluding how to effectively use such medica-
19 tions; and

20 “(iii) the appropriate training of State
21 and local health care providers and first
22 responders on the use of such medications;
23 and

24 “(B) identifies any budgetary resources,
25 personnel resources, licensing requirements, and

1 legal authorities that relevant National Drug
2 Control Program agencies needs to enable the
3 availability of such life-saving emergency drug
4 overdose medications;

5 “(3) A summary of policies in effect before the
6 submission of the report that are administered by—

7 “(A) the Director of the Office National
8 Drug Control Policy;

9 “(B) the Secretary of Health and Human
10 Services; and

11 “(C) each National Drug Control Program
12 agency, as applicable.

13 “(4) A summary of the specific actions taken
14 over the previous 10 years before the submission of
15 the report by the Substance Abuse and Mental
16 Health Services Administration and the Drug En-
17 forcement Administration to coordinate with one an-
18 other and with State health agencies to ensure
19 that—

20 “(A) such treatments, including medica-
21 tions, are accessible to the public; and

22 “(B) appropriate public education on the
23 use of, and the risks and benefits of, such treat-
24 ments, including medications, are readily avail-
25 able.

1 "(c) UPDATES.—Any significant update made to the
2 strategy included in the report required by paragraph
3 (2)(B) after such report is submitted shall be included in
4 the next National Drug Control Strategy submitted to
5 Congress after such update is made.".

○